Connecticut and a coalition of 47 other states and territories announced preliminary court approval of a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to inflate drug prices. The release does not give the date of the court’s preliminary approval, so the event date reflects the press release date.
The approved distribution plan is intended to return settlement funds to eligible consumers who purchased specified generic drugs between May 2009 and December 2019. The manufacturers’ settlements totaled approximately $96.5 million.
Review vendor, distribution, and customer agreements for terms that could facilitate coordination with competitors, including exchanges of nonpublic pricing, market-allocation arrangements, or restrictions on independent pricing decisions. Check pharmaceutical supply and distribution contracts for clear independent-pricing obligations, limits on sharing competitively sensitive information, and audit rights supporting antitrust compliance. Employee and consultant agreements and policies should also address competitor-contact rules, trade association participation, escalation of suspected collusion, and cooperation with investigations.
Entity
Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure
Industry
Healthcare"The coalition previously announced settlements with the manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure"
"totaling approximately $96.5 million"
"defendants used terms like "fair share," "playing nice in the sandbox," and "responsible competitor" to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion."
"Attorney General Tong, along with the Attorneys General of 47 other states and territories"
"09/22/2026"
$96.5M
New Jersey and a coalition of states and territories obtained preliminary approval for a plan to distribute funds from settlements with generic drug manufacturers accused of conspiring to raise drug prices. The settlements total approximately $96.5 million, and eligible consumers may submit claims for compensation.
$694.0M
Connecticut Attorney General William Tong joined 40 other state attorneys general in a settlement with Credit Acceptance Corporation (CAC), one of the nation's largest subprime auto lenders, resolving allegations that CAC originated loans it knew or should have known consumers could not afford and encouraged or failed to prevent dealers from 'packing' CAC loans with unwanted Vehicle Service Contract (VSC) and GAP products. The settlement, announced September 17, 2026 and effective November 2, 2026, directs $694 million in cash restitution and debt relief to consumers, plus an additional $15 million to the states, and imposes injunctive lending reforms. Note: this is a consumer-protection/lending enforcement action rather than a data privacy matter; the violation categories are best-fit mappings to the available taxonomy.
Connecticut Attorney General William Tong issued an advisory that newly enacted privacy laws take effect October 1, 2026, including Public Act 26-64 (SB4), which amends the Connecticut Data Privacy Act, and Public Act 26-15 (SB5), which established the Connecticut Artificial Intelligence Responsibility and Transparency Act (CART Act). The new laws regulate surveillance pricing, facial recognition technology, genetic data collected by direct-to-consumer testing companies, a ban on the sale of precise geolocation data, a data broker registry, AI use in employment decisions, and chatbots offered to children. No enforcement action was taken; this is prospective guidance alerting consumers and businesses to new rights and compliance requirements.
Connecticut Attorney General William Tong joined other state attorneys general in suing the federal government over deals that canceled offshore wind leases in exchange for payments to Bluepoint Wind and Invenergy. The states allege the deals unlawfully used taxpayer funds and failed to follow required procedures, and ask the courts to invalidate the deals and block their implementation.
Connecticut Attorney General William Tong issued a statement regarding a consent decree secured with Warner Bros./Paramount to protect editorial independence of CNN and CBS News. The consent decree establishes an editorial board structure, though the AG expressed disappointment that full divestiture was not achieved.
$384.2M
Connecticut joined 39 other states and the federal government in a $384 million False Claims Act settlement with Abbott Laboratories over allegations that the company failed to manufacture powder infant formula and nutritional therapy products in compliance with federal and state requirements at its Sturgis, Michigan, and Casa Grande, Arizona facilities. Abbott allegedly manufactured formula in conditions that risked microorganism contamination and failed to disclose contamination test results to the FDA during 2019 and 2022 inspections. The settlement resolves claims that Abbott caused false claims to be submitted to the WIC program and state Medicaid programs between January 1, 2018, and December 31, 2022.